Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CANFOUR: targeting IL1RAP for NSCLC or pancreatic cancer

Ahmad Awada • 2 Jun 2019
ASCO 2019
Lung Cancer Non-Small Cell Lung Cancer Pancreatic Cancer CAN04
CANFOUR

Ahmad Awada, MD, PhD, of the Jules Bordet Cancer Institute, Brussels, Belgium, discusses the CANFOUR trial (NCT03267316) investigating CAN04, a monoclonal antibody targeting IL1RAP for patients with non-small cell lung cancer (NSCLC) or pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Ahmad Awada

1:39
Abemaciclib for HR+/HER2- advanced or metastatic breast cancer
Ahmad Awada • 6 May 2021
3:58
BrainStorm: improving prediction, diagnosis and management of brain metastases
Ahmad Awada • 6 May 2021
6:47
Emerging treatments for breast cancer with brain metastases
Ahmad Awada • 6 May 2021
1:15
Changing breast cancer prognoses
Ahmad Awada • 2 Jun 2019

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals